Bharat Biotech

Coronavirus HIGHLIGHTS: Confident Of Getting EMA's Approval In A month For Covishield, Says SII Chief Adar Poonawalla

Covaxin Effectively Neutralises Covid-19's Alpha & Delta Variant: US Health Research Institute

'Pricing Clearly Established For Supplies Outside India': Bharat Biotech On Brazil Covaxin Deal Controversy

Brazil To Suspend USD 324 Million Covaxin Vaccine Deal Over Accusations Of Irregularities

Brazil Govt Faces Probe For Choosing Bharat Biotech's Covaxin Deal Over 'Cheaper' Pfizer Vaccine | All About Controversy

Covaxin Phase 3 Trial Data Shows 77.8% Efficacy, Gets Approval From DCGI's Expert Panel

Covaxin Supplies At Rs 150/Dose ‘Non-Competitive Price, Not Sustainable’: Bharat Biotech Defends Higher Price

US regulator refuses emergency use approval for Covaxin | Audio Bulletin

No Emergency Use Approval For Covaxin In US; Phase 3 Trial Data Expected To Be Published In 7-8 Days, Says Dr VK Paul

Covid Vaccine Prices To Be Revised, Centre In Talks With Serum Institute & Bharat Biotech: Sources

Early Covaxin Study Shows Protections Against Beta & Delta Variants Of Covid-19

Covishield Elicits Better Antibody Response Than Covaxin: Study